Sleep hormone fails to halt MS progression in early trial
NCT ID NCT03540485
First seen Feb 22, 2026 · Last updated May 05, 2026 · Updated 7 times
Summary
This study tested whether adding melatonin to a standard MS drug (ocrelizumab) could slow disability in people with progressive multiple sclerosis. The trial was stopped early after enrolling only 25 participants. It aimed to measure changes in walking, arm function, and thinking, but no clear benefit was found.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Vithas Nisa Sevilla
Seville, Seville, 41950, Spain
-
Virgen Macarena Hospital
Seville, Seville, 41009, Spain
-
Virgen del Rocio University Hospital
Seville, Seville, 41013, Spain
Conditions
Explore the condition pages connected to this study.